Clinical effectiveness of a combination of metformin and ipragliflozin in the management of patients with type-2 diabetes mellitus

Xiaojie Tan¹, Guijuan Sun², Fei Yuan³, Linfang Qu³, Aiqiang Han⁴*

¹Department of Pharmacy, Jiaozhou Central Hospital of Qingdao, ²Department of Encephalopathy, ³Department of Internal Medicine, Shandong Qingdao Integrated Traditional Chinese and Western Medicine Hospital, Shandong, ⁴Department of Health, The Second People's Hospital of Weifang, Weifang, China

*For correspondence: Email: qianghuiaoaohkx@163.com

Sent for review: 25 February 2021 Revised accepted: 3 April 2021

INTRODUCTION

Improved standard of living particularly among the younger population has contributed significantly to drastic rise in cases of diabetes mellitus (DM). Diabetes mellitus (DM) is characterized by reduced pancreatic function and insufficient insulin secretion, which result in hyperglycemia (elevated blood glucose level) and glucosuria (elevated urine glucose level) [1-3]. Diabetes mellitus (DM) is classified as type-1 or type-2 DM. Type-1 diabetes mellitus (T1DM) is
congenital, and the treatment involves insulin injection from birth. Type-2 diabetes mellitus (T2DM), with characteristics of insufficient insulin secretion is attributed to impaired pancreatic function caused by acquired lifestyle habits (lifestyle modification), genetics and other factors. Patients with T2DM are generally treated with oral hypoglycemic drugs in combination with exercise and diet. In the event that oral hypoglycemic drugs fail to meet the desired goal, insulin injections are administered [4-6]. Metformin, the most commonly used oral medication for DM, has the advantages of satisfactory hypoglycemic effect and low side effects. As DM progresses, oral metformin and other hypoglycemic drugs are usually combined. Gliflozin drugs are a class of newly developed oral hypoglycemic agents used for the treatment of T2DM. They act as inhibitors of sodium-glucose cotransporter-2 (SGLT2). Examples of gliflozin drugs are dapagliflozin, empagliflozin and ipragliflozin [7-9]. This study was to investigate the clinical effectiveness of the combination of metformin and ipragliflozin in the treatment of patients with T2DM.

METHODS

Drugs

Metformin was a product of Beijing Taiyang Pharmaceutical Co. Ltd, while ipragliflozin was obtained from AstraZeneca AB (England).

Patients and general information

Patients with T2DM (n = 100) aged 35 – 68 years (mean age = 51.5 ± 16.5 years) were recruited over a 1-year period and randomly assigned to 2 groups (50 patients/group): control and observation groups. Patients in the study group were aged 36 - 66 years (mean age = 51 ± 15 years), while those in control group were aged 35 - 68 years (mean age = 51.5 ± 16.5 years).

Inclusion criteria

The following categories of patients were included in the study: (1) patients diagnosed with T2DM; (2) adult patients aged ≥ 18 years; (3) patients with normal heart, function, lung function and kidney function, without other systemic diseases; (4) patients with no history of drug allergy or drug abuse, and (5) patients who signed written informed consents with their family members. Patients with T1DM, coagulation disorder, or patients on anticoagulant drugs, as well as those with history of insulin treatment were excluded from the study. The study protocol was reviewed and approved by the Human Ethics Committee (approval no. 2017-234) of The Second People's Hospital of Weifang, Weifang, China [10].

Study design

The control group patients were given orally with metformin at a dose of 500 mg/kg twice a day, while patients in study group received 50 mg ipragliflozin/kg, once a day orally, in addition to metformin. Treatment in the two groups lasted 3 months, during which the patients paid close attention to their diets, carried out moderate exercise, and were not allowed to use other antidiabetic drugs.

Treatment indices

Peripheral venous blood (5 mL) was drawn from patients before and after treatment, and centrifuged at 3000 rpm for 10 min to obtain plasma that was used for analysis. Fasting blood glucose (FBG) and 2-h PBG were determined employing automated biochemical analyzer. Fasting blood glucose (FBG) of 3.9 - 6.1 mmol/L and 2-h PBG < 11 mmol/L were taken as normal. Glycated hemoglobin (HbAlc) concentration was determined using immuno-turbidimetric method. Glycated hemoglobin concentrations within the range of 4.99 - 6.79 % were considered normal. Body fat of patients was measured every 1 month for 3 months.

Determination of curative effect

Curative effect was determined by following reductions in blood glucose and improvements in clinical symptoms. Curative effect was classified into three: remarkably effective, effective and ineffective. The conditions applicable to each classification were: remarkably effective: clinical symptoms disappeared, FBG < 6.1 mmol/L, 2-h PBG < 11.0 mmol/L, and HbAlc < 6.79 %; effective: obvious improvements in clinical symptoms, with FBG, 2-h PBG, and HbAlc within normal ranges; ineffective: no improvements in clinical symptoms, and no appreciable reductions in blood glucose levels. The total effectiveness was calculated as shown in Eq 1.

A (%) = B + C …………. (1)

Note: A-Total effectiveness; B-remarkably effective cases; C-effective cases

Measurement of safety

Adverse reactions such as gastrointestinal reaction, duration of hypoglycemia and abnormal
liver and kidney functions were recorded and analyzed.

**Statistical analysis**

Data analysis was performed with SPSS (20.0), expressed as mean ± SEM. Inter-group comparison was conducted by using Student t-test and Chi-squared test. GraphPad Prism version 7 was used to construct graphs. Values of \( p < 0.05 \) were declared as significant differences.

**RESULTS**

**Clinicopathological data**

No significant differences between the two groups in clinicopathological data for the patients such as gender, age, course of disease, and comorbidities, were detected \((p > 0.05; \text{Table 1})\).

**Blood glucose levels of patients**

The levels of FBG, 2-h PBG and BBG observed a sharp decline in both groups of patients after treatment \((p < 0.05\). However, the study group yielded lower levels of FBG, 2-h PBG and BBG \((p < 0.05; \text{Figure 1})\).

**Levels of glycated hemoglobin of patients in each group**

As shown in Figure 2, after treatment, in comparison with the control group in terms of the HbA1c level, the study group garnered an apparently lower result \((p < 0.05)\).

**Comparison of curative effect**

After treatment, a larger number of remarkably effective cases and a higher total effectiveness were observed in the study group \((p < 0.05; \text{Table 2})\).

**Effect of treatment on incidents of adverse reactions**

There were adverse reactions such as nocturnal hypoglycemia, low vision, chronic nephritis, and constipation in both groups. However, incidents of adverse reactions were markedly reduced in the study group \((p < 0.05)\). See Table 3.

![Figure 1: Comparison of blood glucose levels. *\( p < 0.05 \) (FBG of study group compared with control group); **\( p < 0.05 \) (2-h PBG of study group compared with control group); ***\( p < 0.05 \) (BBG of study group compared with control group)](image1)

![Figure 2: Comparison of glycated hemoglobin level; *\( p < 0.05 \), as compared to the control group)](image2)

**Table 1: General patient profile**

| Parameter                  | Group       | Control      | \( \chi^2 \) | P-value |
|----------------------------|-------------|--------------|--------------|---------|
| Gender                     | Study       | Control      |              |         |
| Male                       | 26          | 27           | 0.04         | 0.84    |
| Female                     | 24          | 23           |              |         |
| Age (years)                | 53.29 ± 6.38| 53.40 ± 6.59 | 0.08         | 0.93    |
| Height (cm)                | 173.26 ± 8.81| 173.59 ± 8.66| 0.19         | 0.85    |
| Weight (kg)                | 71.04 ± 5.39| 70.99 ± 5.42 | 0.05         | 0.96    |
| Course of disease (years)  | 6.47 ± 2.08 | 6.38 ± 2.11  | 0.21         | 0.83    |
| History of smoking (years) | 5.81 ± 1.33 | 5.76 ± 1.41  | 0.18         | 0.86    |
| History of drinking (years)| 10.00 ± 2.34| 9.86 ± 2.05  | 0.32         | 0.75    |
| Hypertension (cases)       | 13          | 15           | 0.20         | 0.66    |
| Hyperlipidemia (cases)     | 8           | 7            | 0.08         | 0.78    |
Table 2: Comparison of effectiveness of treatment

| Group   | Markedly effective | Effective | Ineffective | Total effectiveness (%) |
|---------|--------------------|-----------|-------------|-------------------------|
| Study   | 35                 | 13        | 2           | 96                      |
| Control | 10                 | 26        | 14          | 72                      |
| \( \chi^2 \) |                    |           |             | 10.710                  |
| \( P \)-value |                 |           |             | 0.001                   |

Table 3: Comparison of incidents of adverse reactions

| Group      | Nocturnal hypoglycemia | Impaired vision | Chronic nephritis | Constipation | Incidence of adverse reactions (%) |
|------------|------------------------|-----------------|-------------------|--------------|-----------------------------------|
| Observation| 0                      | 1               | 0                 | 3            | 8%                                |
| Control    | 8                      | 5               | 1                 | 6            | 40%                               |
| \( \chi^2 \) |                     |                  |                   |              | 14.04                             |
| \( P \)-value |                  |                  |                   |              | < 0.001                           |

Effect of treatment on body fat

Two groups did not differ regarding body fat between the two groups before treatment (\( p > 0.05 \)). However, after treatment, body fat of patients in study group was notably and time-dependently reduced (\( p < 0.05 \); Figure 3).

![Figure 3: Changes in patients' body fat after treatment](image)

DISCUSSION

Diabetes mellitus (DM) impacts negatively on the quality of life of patients. The disease is characterized by micro- and macrovascular complications, and high morbidity. Diabetics rely on long-term hypoglycemic medication which puts considerable economic pressure on them and their family members [1-13]. Hypoglycemic therapy alone cannot sufficiently protect the secretory function of pancreatic \( \beta \) cells, since this may decline with duration of the disease. Thus, diabetic patients are advised to pay close attention to their diets and carry out regular exercises.

Treatment of asymptomatic DM requires constant monitoring of FBG, 2-h PBG and BBG [14-16]. The goals in diabetic care are to eliminate diabetes symptoms and to prevent, or at least slow the development of complications. Type-2 diabetes mellitus (T2DM) is managed with non-insulin medications, insulin (in extreme cases), weight reduction and dietary changes. Long-term hyperglycemia results in cardiovascular and cerebrovascular diseases, nephropathy, retinopathy, neuropathy and endocrine disorders. Thus, maintenance of blood glucose within a safe range is of utmost importance [17-20]. The simultaneous use of different hypoglycemic drugs predisposes patients to persistent hypoglycemia due to drug interactions, and fatality may result in severe cases. Adverse reactions often accompany such drug combinations. Ipragliflozin and metformin are common oral hypoglycemic drugs used for the treatment of T2DM.

This study evaluated the clinical effectiveness of combination of metformin and ipragliflozin in the treatment of patients with T2DM. The results showed that FBG, 2-h PBG, BBG, HbA1c, body fat and incidents of adverse reactions were markedly reduced in T2DM patients treated with the combination of metformin and ipragliflozin, relative to those treated with metformin alone. These results are indicative of that the combination therapy may exert an effective efficacy in stabilizing blood glucose. Since effectiveness of DM treatment is majorly determined by blood glucose and glycated hemoglobin indices, as well as incidents of adverse reactions, the combination therapy of metformin and ipragliflozin may be more effective than monotherapy with metformin in alleviating the complications of DM. These results are in agreement with previous reports [21].
Limitations of the study

This study has several limitations with respect to interpretations of results. First, this study was conducted in a single region, and they might not have representability. Second, the study population was small, so the results should be interpreted with caution.

CONCLUSION

The results obtained in this study show that the combination of metformin and ipragliflozin is safe and more clinically effective in the treatment of T2DM than metformin monotherapy.

DECLARATIONS

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Youn PH, Kyoungdo H, Youngwook K, Hwan KY, Joon SY. The risk of hip fractures in individuals over 50 years old with prediabetes and type 2 diabetes – A longitudinal nationwide population-based study. Bone. 2021; 142: 115691.
2. Taeko O, Kazuya F, Mayuko HY, Masahiko Y, Masaru K, Yasuhiro M, Midori I, Takaho Y, Hiroyasu S, Satoru K, et al. Severity of hypertension as a predictor of initiation of dialysis among study participants with and without diabetes mellitus. J Invest Med. 2020; 69(3): 724-729
3. Balev B, Tzotchev K, Usheva N, Galcheva S, Chalakova T, Iotova V, Bocheva Y, Yotov Y. Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality. Cur Diabetes Rev. 2021;17(1):37-54.
4. Abdul-Razzak KK, Alkhataitbeh MJ, Saadeh NA, Smadi SA. High Prevalence of Vitamin D Deficiency and Correlation with Cystatin-C and Other Cardiovascular and Renal Risk Biomarkers in Patients with Type 2 Diabetes Mellitus Complicated with Hypertension. Cur Diabetes Rev 2021; 17(1):81-90.
5. Guo SJ, Wang GF, Wang, Yang ZX. Ligustilide alleviates the insulin resistance, lipid accumulation, and pathological injury with elevated phosphorylated AMPK level in rats with diabetes mellitus. Journal of Receptors and Signal Transduction. 2021; 41(1):85-92.
6. Muhammed S, Khalid M. Volumetric and aggregation properties of metformin hydrochloride in methanol in temperature range of (288.15 – 318.15) K. Surfaces and Interfaces. 2021; 22:100852.
7. Kristian L, Walid A, Raif H. The effect of Nigella sativa oil and metformin on male seminal parameters and testosterone in Wistar rats exposed to an obesogenic diet. Biomedicine & Pharmacotherapy. 2021; 133: 110855.
8. Heng C, Guoliang S, Lin L, Sangang H, Tianfu W. In vitro and in vivo synergistic anti-lumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma. European Journal of Pharmacology. 2021; 891 :173757.
9. Kamal MD, Mostafa KM, Kamel BM, Abdelbary AA, Mohamed EA. Autophagy blockade mechanistically links proton pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of metformin/enalapril. Life Sciences. 2021; 265 :118818.
10. Lo Presti R, Hoppes E, Caimi G. Gelatinases and physical exercise: A systematic review of evidence from human studies. Medicine (Baltimore). 2017;96(37): e8012.
11. Gang L, Guo S, Wu Q, Wu L. Investigation of the metformin drug-sensing mechanism on the decorated and pristine boron nitride semiconductor: ab-initio study. Molecular Physics. 2020; 118 (24):1-8.
12. Lautsch D, Alsumali A, McLeod E, Kuang Y, He J, Singh R, Nevo A, Arnet U, Uyel J, Rajpathak S. Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis. Diabetes Therapy. 2021; 12(1):389-418.
13. Aslı Y, Murat B, Zeyneb B. The efficacy of different insulin-sensitizing agents on treatment outcomes in patients with polycystic ovary syndrome who underwent in vitro fertilization: A retrospective, record-based, comparative study. Journal of Gynecology Obstetrics and Human Reproduction. 2021; 50(1): 102006.
14. Youngoo L, Jungnam J, Jin LY, Kyung LE, Sohyun P, Tae-Sung K, Soo-Hyun L, Young KS, Gyung-Ah W, Minjoung P, Mi-Jung K, Soo LJ, Ji-Youn H. Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer. 2021; 151:8-15.
15. Mohammadi H, Manouchehri H, Changizi R, Bootorabi F, Khorramizadeh MR. Correction to: Concurrent metformin and silibinin therapy in diabetes: assessments in zebrafish (Danio rerio) animal model. Journal of Diabetes & Metabolic Disorders. 2020; 19(2):1233-1244.

16. Jones NS, William RG. Metformin reduces behavioral, but not metabolic, disturbances associated with high-fat diet. Alzheimer's & Dementia. 2020; 16: e047591.

17. Zhao S, Chen Y, Fan ZQ, Zhang BR. Metformin treatment attenuates tau seeding in neuritic plaques. Alzheimer's & Dementia. 2020; 16: e041470.

18. Borah B, Devi TG. Molecular property analysis of the interacting state of L-Threonine and Metformin: An experimental and computational approach. Journal of Molecular Structure. 2020; 1221: 128819.

19. Edyta S, Paulina F, Bernadetta K, Karolina S, Pawel H, Fleszar MG. The impact of Sample Handling Time on metformin serum concentration. Biomedicine & Pharmacotherapy. 2021; 133 :110971.

20. Francesco Z, Kamlesh K, Nikolaus M, Davies MJ. First-line treatment for type 2 diabetes: is it too early to abandon metformin. The Lancet 2020; 396(10264):1705-1707.

21. Min L, Na S, Scepter X, Xuehua J. Systematic evaluation of the efficacy and safety of Iglitazine combined with other oral hypoglycemic agents in the treatment of type 2 diabetes. Chin J Hosp Pharm 2008; 38(04): 420-425.